Monica L Guzman, PhD

Overview

Cancer stem cells (CSCs) are thought to initate and perpetuate several malignancies including acute myelogenous leukemia (AML) and breast cancer. Recent evidence has shown that cancer stem cells (CSCs) represent a relatively quiescent subpopulation of cells that is refractory to current therapeutic treatments. Thus, it has been suggested that this population of CSCs may result in disease relapse. Therefore, CSCs represent a critical therapeutic target for improving clinical outcomes. Specifically, we have demonstrated that AML stem cells exist in a molecular state that is unique from their normal hematopoietic counterparts. Since these features are absent in normal cells, I successfully employed both molecular genetic and small molecule strategies that exploit these differences to selectively ablate AML at the bulk, stem, and progenitor level, with no appreciable toxicity to their normal hematopoietic counterparts.

For more information visit our website.

Highlights

1
Nature communications · 2022
NMNuria Mencia Trinchant DCDuane C Hassane GJGail J Roboz MLMonica L Guzman
PMID: 35484102PMCID: PMC9050731DOISenior author66 citations
2
Blood · 2021
CMCem Meydan GJGail J Roboz ZCZhengming Chen CEChristopher E Mason+1 more →MLMonica L Guzman
PMID: 32911532PMCID: PMC7885821DOISenior author34 citations
3
Cell death & disease · 2023
EGEncouse Golden KVKoen Van Besien SCSilvia Chiara Formenti MLMonica L Guzman
PMID: 37142568PMCID: PMC10160073DOISenior author38 citations

Publications

143

Funding

37 View NIH portfolio on RePORTER ↗

Active

8 grants

Sub-PI
Tissue-Engineered Models of Lymphatic Drainage in Breast Cancer
National Cancer Institute · 2023–2028 · via Cornell University - Ithaca
R01CA279560-02
Co-I
Mutational and Aging Risk Factors for Myelodysplastic Syndrome
U.S. Department of Defense · 2023–2027
HT9425-23-1-0431
Co-I
Clonal Hematopoiesis as a determinant for bone marrow toxicities for targeted radiation therapies in prostate cancer.
U.S. Department of Defense · 2022–2027
W81XWH-22-1-0375
MPI
Mechanism of elF4E mediated transformation
National Cancer Institute · 2021–2027 · via Northwestern University· 2 renewals
R01CA098571-21
Co-I
Pre-malignant mutation landscape and risk factors for progression to hematologic cancers
National Cancer Institute · 2021–2027
R01CA248747-04
PI
BLOSSoM (Building Leaders with Opportunities for Success in Science of the Meyer Cancer Center)
Parker Institute for Cancer Immunotherapy · 2024–2026
PICI IC-595
KP
Characterizing the Role and Targeting of the histone methyltransferase Setd2 in Multiple Myeloma
International Myeloma Foundation · 2024–2025
IMF 233969-01
Co-I
Janssen Biopharma Agreement
Janssen Biotech Inc. · 2020–2025BioPharma Alliance
BP 212999-01

Completed grants (29)

Sub-PI
Alternatively spliced cell surface proteins as drivers of leukemogenesis and targets for immunotherapy
National Cancer Institute · 2023–2025 · via H. Lee Moffitt Cancer Center & Research Institute
R21CA280367-02
Sub-PI
Targeted Small Molecule Inhibitors for Inv(16) Leukemia
National Cancer Institute · 2018–2024 · via University of Virginia
R01CA234478-05
Sub-PI
Oncogenic Impact of eIF4E-dependent RNA export in cancer
National Cancer Institute · 2023–2024 · via Universite de Montreal
R01CA080728-21A1
Co-I
Clonal Hematopoeisis in HIV and Aging
National Institute on Aging · 2020–2024
R21AG066552-02
PI
3D co-culture system to characterize and target leukemia stem cells
National Cancer Institute · 2020–2024
R21CA245454-01A1
MPI
ECOG-ACRIN NCORP Research Base - CT - E2906 Integrated nRT BIQSFP
National Cancer Institute · 2022–2023 · via University of Virginia
UG1CA189828-09S1
PI
SRA BridgeMedicines
BridgeMedicines · 2021–2022Contract
BM 213565-01
PI
Research Mobility Grant (Aikaterini E Miari)
European Hematology Association · 2022–2022
EHA 225419-01
Sub-PI
Development of Novel Anti-Leukemia Agents Targeting the Menin-MLL Interaction
National Cancer Institute · 2017–2022 · via University of Michigan
R01CA160467-10
Sub-PI
The Development of Novel 3-D Methods to Study MDS Ex Vivo
Edward P. Evans Foundation · 2019–2021 · via Vanderbilt University Medical Center
VUMC 78320-02
MPI
The impact of human spaceflight on clonal hematopoiesis
National Aeronautics and Space Administration · 2020–2021
80NSSC20K1841
PI
Specific Ablation of AML Stem Cells Through Selective Targeting of HSP70 in the Stem Cell Compartment
American Society of Hematology Inc · 2019–2021
ASH 192421-01
Co-I
Integrative Single-cell Analysis of Hematological Malignancies
Daiichi Sankyo Co., Ltd. · 2018–2020Contract
DS 192276-01
PI
Preclinical evaluation of UCART (allogeneic engineered CAR-T Cells) activity against primary Acute Myeloid Leukemia (AML) samples (CLL Agreement)
Cellectis, Inc · 2019–2020Contract
BP 193410-01
Sub-PI
Collaboration with Mark Williams of GCU to Analyze Macrophages
British Society for Haematology · 2019–2020 · via Glasgow Caledonian UniversityContract
SA 201072-01
Sub-PI
Preclinical Studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML
National Cancer Institute · 2018–2020 · via Synactix Pharmaceutical, Inc
R41CA224830-01
Sub-PI
Development of small molecules targeting Ring1B-Bmi1 E3 ligase in leukemia
National Cancer Institute · 2016–2019 · via University of Michigan
R01CA207272-02
MPI
Biomarkers for predicting response to Hsp90 therapy
NCI · 2013–2019 · via NIH RePORTER
R01CA172546-05
PI
PDX Amendment
LAM Therapeutics · 2017–2018Contract
SRA 183684-01
Co-I
LAM-003 Clinical Trial_Lee_Guzman
LAM Therapeutics · 2017–2018Contract
LT 181966-01
PI
Planned Studies in AML
TeamedOn International · 2018–2018Contract
SRA 182066-01
Sub-PI
Predictors of Response to HSP90i
National Cancer Institute · 2013–2018 · via Sloan-Kettering Institute for Cancer Research
MSKCC 5 R01CA172546-05
Sub-PI
Pharmacological Modulation of Epigenetic Changes in AML
National Cancer Institute · 2013–2018 · via Beckman Research Institute of the City of Hope· 2 renewals
R01CA102031-10
KP
Delineating Clinical Response with Single-Cell Omics
AbbVie Inc. · 2016–2017Contract
Abbvie RAA
Sub-PI
A New Small Molecule Targeted Therapeutic for Acute Myeloid Leukemia
National Cancer Institute · 2016–2017 · via TeamedOn International
R43CA203172-01
PI
Identification of Novel Therapies to Ablate Chemoresistant Myeloid Leukemia Stem Cells during Remission
Office of the Director, NIH · 2010–2015
DP2OD007399-05
Sub-PI
ECOG-ACRIN Integrated Leukemia Translational Research Center
National Cancer Institute · 2014–2015 · via Montefiore Medical Center
No publications yet
U01CA180827-02 EW
KP
Center on the Microenvironment and Metastasis
National Cancer Institute · 2009–2015 · via Cornell University - Ithaca
U54CA143876-05 EW
PI
A Role for Elevated Autophagy in Survival and Chemoresistance of Leukemia Stem Cells
National Cancer Institute · 2012–2014
R21CA158728-02

News mentions

2 View all WCM news ↗

Immune Therapy Targets Cells that Cause Leukemia Relapse
June 2, 2022
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia, a type of blood cancer, and proved effective in animal models of the disease.
Scientists Build the First Global Database and Roadmap for CAR Therapy Clinical Trials
January 6, 2020
Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them.

Overview

Highlights

Publications

Funding

Active

News mentions

External relationships

Ownership

Proprietary Interest